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Abstract 
Aims/ hypothesis 
Evidence that the beta-cells of human patients with type 1 diabetes can be infected with enterovirus is 
accumulating but it remains unclear whether such infections occur at high frequency and are 
important in the disease process. We have now assessed the prevalence of enteroviral vp-1 capsid 
staining in a large cohort of autopsy pancreases of recent-onset type 1 diabetic patients and a range of 
controls. 
Methods 
Serial sections of paraffin-embedded pancreatic autopsy samples from 72 recent-onset type 1 diabetes 
patients and up to 161 controls were immunostained for insulin, glucagon, enteroviral vp1, double-
stranded RNA activated protein kinase R (PKR) and MHC class 1. 
Results 
Vp1 immunopositive cells were detected in multiple islets of 44/72 young recent-onset type 1 diabetic 
patients, compared with a total of only 3 islets in 3/50 neonatal and paediatric normal controls. Vp1 
staining was restricted to insulin containing beta-cells. Among the control pancreases vp1 
immunopositivity was also observed in some islets from 10/25 type 2 diabetic patients. A strong 
correlation was established between islet cell vp1 positivity and PKR production in insulin-containing 
islets of both type 1 and type 2 diabetic patients, consistent with a persistent viral infection of the 
islets.  
Conclusion/ Interpretations 
Immunoreactive enteroviral vp1 is commonly found in the islets of recent-onset type 1 diabetes 
patients, but only rarely in normal paediatric controls. Vp1 immunostaining was also observed in 
some islets of type 2 diabetes patients, suggesting that the phenomenon is not restricted to type 1 
diabetes patients. 
 
Keywords: Type 1 diabetes, type 2 diabetes environmental triggers, enterovirus, insulitis, islets of 
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 Abbreviations: CVB – Coxsackie B virus; ICI- insulin-containing islets; IDI- insulin deficient islets; 
MHC – major histocompatibility antigen; PKR – double-stranded RNA activated protein kinase R; 
Vp1 – enteroviral capsid protein vp1;  
 
 
Introduction 
Enteroviral infection has long been implicated in triggering autoimmunity, islet inflammation 
(insulitis) and beta-cell death in human type 1 diabetes. Much of the evidence is circumstantial [1] but 
includes observations that antibodies against common Coxsackie B enteroviruses (CVB) and 
enteroviral RNA occur more frequently in the circulation of recent-onset type 1 diabetics than in 
controls [2-10].  
 
More direct support for a viral aetiology has come from the demonstration that a strain of CVB4, 
isolated from the pancreas of a recent-onset type 1 diabetic patient, was capable of inducing diabetes 
in mice [11]. In addition, the presence of enteroviral RNA was revealed by in situ hybridisation in the 
islets of four recent-onset type 1 diabetes cases [12] and the enteroviral capsid protein, vp1, was 
detected in the beta-cells of 2 of 5 patients with type 1 diabetes, and in a sixth diabetic patient who 
had received a recent pancreatic transplant [13]. Electron microscopic analysis revealed the presence 
of virus particles within the islet beta cells of vp1 positive cases, and a strain of CVB4 was isolated 
from the pancreas of one patient. This was capable of infecting normal human islets in vitro, resulting 
in their functional impairment [13].  
 
Enteroviral infection can result in the production of double stranded RNA (dsRNA) within cells [14] 
and double-stranded RNA activated protein kinase R (PKR) was upregulated in islets infected by 
CVB5 in vitro [15]. Similarly, CVB-infected islets produced interferon-alpha in vitro [16] and this has 
been associated with hyperexpression of class I MHC [17].  
 
In view of these findings, we considered it important to establish the prevalence of immunoreactive 
vp1 staining in the islets of a large cohort of recent onset type 1 diabetes cases and in a wide range of 
relevant controls. We have also established whether an antiviral response is mounted in the islets of 
these patients by immunostaining for PKR. Finally, we have assessed whether vp1 staining occurs 
independently of insulitis. 
 
 
Methods  
Subjects 
Formalin fixed paraffin embedded pancreatic autopsy tissue from 72 patients with recent onset type 1 
diabetes mellitus, whose pancreatic histology has been described previously [18] was used, with 
ethical permission. The cases were from various hospitals and had been fixed in buffered formalin, 
formol saline, formol saline with added mercuric chloride, or Bouin’s fixative, with no standardisation 
of fixation time. The cohort consisted of 41 female and 31 male patients with a mean age of 
12.65±1.1years (range 1 to 42 years) and a mean time since diagnosis of 8.2±4.1 months; (range 0-6 
years).  Control autopsy tissues, fixed in a similar variety of fixatives, were 5 culture proven 
Coxsackie virus-infected neonatal pancreases and hearts; 11 normal neonatal pancreases (<1 month); 
3 normal neonatal hearts; 39 normal paediatric pancreases (age range 6 weeks-17 years); 11 
pancreases from cystic fibrosis patients with a mean age of 8.1±1.7 years (age range 2-19 years); 69 
normal adult pancreases and 25 pancreases from adult patients with type 2 diabetes.  
 
 
Immunohistochemistry 
Serial sections (4μm) were cut from each case and mounted on glass slides coated in (3-
Aminopropyl)-triethoxysilane (Sigma, Poole, Dorset, UK). Sections were processed and labelled 
using a standard immunoperoxidase technique for paraffin sections. With the exception of glucagon, 
insulin and MHC class 1, all other antigens were unmasked by heat-induced epitope retrieval. 
Sections to be labelled with anti-PKR and anti-CD45 were heated in 10mM citrate buffer pH 6.0 
while those to be labelled with DAKO anti-enteroviral vp1 (5D8/1; DAKO, Glostrup, Denmark), 
polyclonal anti-vp1, or anti-Pan-enterovirus (9D5; Millipore, Livingston, UK) were heated in 1mM 
EDTA, pH 8.0. See Supplementary Table (online) for details of antibody dilutions and sources.  
 
Primary antibodies were applied for 30 min at room temperature (except for anti-Pan-enterovirus 
(9D5) and anti-PKR which were incubated overnight at 4°C) and Dako REAL™ Envision™ 
Detection System used for antigen detection. Some slides were processed in the absence of primary 
antibody or with isotype control antisera to confirm the specificity of labelling. Slides were analysed 
by light microscopy. 
 
Immunofluorescence staining 
To determine the islet cell subtypes infected by enterovirus, double immunofluorescence staining was 
performed. Anti-insulin, anti-glucagon and anti-vp1 reactivity were detected using an Alexa Fluor 
488-conjugated anti-guinea pig antibody, an Alexa Fluor 488 anti-rabbit antibody and an Alexa Fluor 
568 conjugated anti-mouse antibody respectively (Invitrogen, Paisley, UK). Sections were mounted 
using Vectashield medium (Vector Labs, Burlingame, Ca, USA) and were observed using a Zeiss 
LSM510 Meta confocal microscope. 
 
Statistics 
Statistical analysis was performed either by the Chi squared test or Students t-test, as appropriate. 
 
 
Results 
Vp1 staining in the islets of recent-onset Type 1 diabetic patients  
In order to confirm the utility of the DAKO enteroviral antibody used previously to identify vp1 
immunoreactivity in the pancreas [13, 19] and intestine [20] of patients with type 1 diabetes, we 
initially examined its reactivity in formalin-fixed, paraffin embedded, heart and pancreas samples 
taken from 5 neonates having fulminant, fatal Coxsackie B infection. Cardiac myocytes and many 
pancreatic islets from these samples contained cells which were strongly immunopositive for vp1 
(Figure 1a and Figure3a). By contrast, none of the islets examined in normal pancreas sections 
recovered from 11 non-diabetic neonates, nor the myocytes in hearts of neonates without myocarditis, 
were immunopositive for vp1.  
 
Probing of the pancreases from our cohort of type 1 diabetes patients with the DAKO anti-vp1 
antibody revealed the presence of small numbers of intensely stained cells in multiple islets from the 
majority of cases (Figure 1b-c). These immunopositive islet cells were readily distinguishable from 
the surrounding unstained endocrine cells (which formed the majority in all cases) suggesting that the 
antibody did not label an endogenous islet cell antigen. To facilitate quantitative analysis, a case was 
deemed positive for vp1 when at least one intensely stained endocrine cell was present in an islet 
within any given section. Using this criterion, 44 of the 72 (61%) recent-onset type 1 diabetes cases 
were positive for enteroviral vp1 antigen (Figure 1g) and most contained multiple immunopositive 
cells in a range of islets. Comparison of the age and sex of the patients failed to reveal any significant 
differences between the vp1-positive and vp1-negative cases. However, the duration of diabetes 
tended to be lower in the vp1-positive group (2.32±0.8 months vs 16.5±8.0 months; p=0.06).  
 
Occasional islet cell vp1 immunopositivty was detected in the pancreases of 3 of 39 (7.7%) non-
diabetic paediatric cases (Figure 1e, g) but this amounted to a total of only 4 endocrine cells among 
the entire islet population examined. This was significantly lower than that observed in the patients 
with type 1 diabetes (X
2
=29.71, p<0.001). A series of 11 paediatric cystic fibrosis pancreases was also 
examined for vp1 immunopositivity to determine whether the viral protein is found commonly in 
patients with another pancreatic inflammatory disease. Of these, two contained multiple vp1 positive 
islets similar to those seen in the type 1 diabetes patients (not shown). Importantly, subsequent 
examination of the case histories of these patients revealed that the two with vp1 immunopositivity in 
the islets, also had diabetes. None of the vp1 negative cystic fibrosis cases had diabetes.    
 
 
Vp1 immunostaining is restricted to insulin-containing islets 
In the pancreas in recent onset type 1 diabetes approximately 60% of the islets are insulin deficient 
and the remainder contain residual insulin secreting beta cells [18]. An analysis was made of the 
distribution of vp1 positive cells between insulin deficient islets (IDI) and insulin containing islets 
(ICI) in serial sections from 10 patients with frequent vp1 positive endocrine cells. A total of 342 ICIs 
were analysed and 269 (78.7%) were found to be positive for vp1.  By contrast, only 16 of 611 (2.6%) 
IDIs showed evidence of vp1 within the plane of the section (Figure 2a).  This suggests that beta cells 
contain the viral protein and confirmation was achieved more directly by double immunofluorescence 
staining for either insulin or glucagon together with vp1 (Figure 2b). This revealed that staining of the 
viral antigen was restricted to a minority of insulin-positive cells. Similar results were verified in 5 
separate cases in which an average of 32 islets were examined per section.  
  
The presence of CD45
+
 immune cells was also examined to determine whether a relationship existed 
between vp1 immunopositivity and the extent of insulitis in type 1 diabetes patients. A total of 200 
vp1 positive ICIs were studied (from 7 patients) and 123 (61.5%) of these showed no evidence of 
inflammation (i.e. they were negative for CD45).  
 
Verification of islet vp1 staining with other enteroviral antisera 
To confirm that the DAKO antiserum was detecting enteroviral vp1 in the islets of type 1 diabetes 
patients, the staining pattern was compared with that obtained using a second, polyclonal antiserum 
raised against vp1 (designated Kdf), and an additional pan-enteroviral monoclonal antibody, not 
specifically directed against vp1 (clone 9D5). Initially these antisera were tested in normal and 
Coxsackie-infected neonatal human heart. This confirmed that similar regions of the tissue were 
stained with each antibody in infected tissue (examples for DAKO and Kdf are shown in Fig 3) and 
that staining was absent from normal control hearts. Under optimal conditions, the DAKO antiserum 
appeared to be the most sensitive of the three, since staining was more intense and extensive with this 
antibody. It also gave more consistent results on tissues fixed in a variety of fixatives.  
 
Comparison of staining with the three antisera applied to serial sections of pancreas is presented in 
Figure 4 (a-f) together with a quantitative analysis from 11 patients (Table 1). The images show islets 
from two different patients stained with either the DAKO vp1 (Figure 4a, e), Kdf (Figure 4b, f) or 9d5 
(Figure 4c) antibodies and demonstrate that intensely positive islet cells could be detected in the same 
islets with these reagents. Of the 11 patients studied in detail, 1 Bouin’s fixed case had islets stained 
by all 3 antisera and at least a further 3 had positive immunostaining in ICI with two antibodies. The 
DAKO antiserum appeared most sensitive since it stained one or more of the ICI in all 11 cases.  No 
IDI were stained with any of the antisera. 
 
Correlation between islet vp1 staining and additional markers of viral infection 
Serial sections of pancreas were next stained with antibodies to insulin, vp1, PKR and MHC-1 in 6 
vp1 positive type 1 diabetes patients to determine whether vp1 staining correlated with other markers 
of viral infection and autoimmunity. Representative insulin containing islets from one of these 
patients are shown in Figure 5a and a representative insulin-deficient islet is also shown for 
comparison.  PKR staining correlated with vp1 immunopositivity in 154 of 177 (87.0%) ICIs analysed 
in the type 1 diabetes patients (Figure 5a and b) whereas it was not detected in any islets of 5 non-
diabetic age-matched control pancreases. PKR staining was only rarely observed in insulin deficient 
islets. Islet cell MHC-1 hyperexpression was detected in all of the type 1 diabetes cases analysed and 
this correlated with the presence of insulin (Figure 5a). All vp1 positive islets were found to hyper-
express MHC-1, but so did many vp1 negative insulin-containing islets.  MHC-1 was not hyper-
expressed in any neonatal or paediatric control pancreas. 
 
 
Vp1 staining in sections of pancreas from Type 2 diabetic patients and from non-diabetic adults 
The study was extended to include pancreas samples recovered post mortem from 69 normal adults 
and 26 patients with type 2 diabetes. Islet endocrine cell immunopositivity for vp1 (DAKO antiserum) 
was observed in 9 of 69 (13.0%) normal pancreases (Figure 6ai and b). Of 25 type 2 diabetic patients 
analysed, 10 (40%) contained a range of islets having intensely positive cells (Figure 6aii and b; 
X
2
=7.89, p<0.01vs normal pancreas). 
 
A more detailed comparison of the frequency of vp1 positive islets in 10 type 1 and 6 type 2 diabetic 
pancreases as well as 7 non-diabetic adult pancreases was performed (Fig 6c). The cases were chosen 
at random among pancreases which had vp1 positive islets. 70/251 (27.9%) islets contained vp1 
positive endocrine cells in the 6 type 2 diabetes pancreas sections studied whereas only 15/210 (7.1%) 
islets from 7 normal adult pancreas contained equivalent cells (Figure 6C; X
2
=32.81, p<0.001). This 
compared with 269/342 (78.7%) vp1 positive insulin containing islets in the 10 type 1 diabetes cases 
studied in detail (X
2
=152.31, p<0.001; vs type 2 diabetes). In the islets of patients with type 2 diabetes 
islets that were vp1 positive, PKR immunopositivity was also often detected (Figure 5a and 6d). 
Hyper-expression of MHC-1 was not seen in any islet from type 2 diabetes patients (Figure 5a) nor in 
non-diabetic adult pancreases.  
 
Finally, in some cases, focal pancreatic centroacinar cells in the exocrine tissue and some smooth 
muscle cells in vein walls were stained positively by the DAKO anti-vp1 serum (Figure 6aiii-iv).  
Such staining was also seen, but much less frequently, in the neonatal and paediatric pancreases of 
both diabetic and non diabetic patients, and it was never observed with the kdf antiserum.  
 
Discussion 
Circumstantial evidence has implicated enteroviral infection in the aetiology of type 1 diabetes but 
direct support for the hypothesis that islet cell enterovirus infection is a common occurrence in the 
disease has been more difficult to obtain [1]. However, it was recently reported that the enteroviral 
capsid protein, vp1, was detectable in a range of beta-cells in 2 of 5 recent onset type 1 diabetic 
patients and in another diabetic patient who had received a pancreatic transplant, but not in 26 non 
diabetic controls [13]. In order to verify and extend this finding, we have analysed the prevalence of 
pancreatic islet vp1 immunopositivity in 72 recent-onset type 1 diabetic patients and in a range of 
controls. The results reveal a prevalence of islet vp1 immunopositivity of ~ 61% in type 1 diabetic 
patients, with almost no equivalent staining in the pancreases of neonatal and paediatric non diabetic 
controls. Double immunofluorescence studies showed that vp1 staining was confined to beta-cells. 
Thus, the proposal that vp1 immunopositivity may be common in the insulin-secreting cells of type 1 
diabetic patients is supported by this more extensive analysis.  
 
An important consideration is the identity of the antigen labelled by the DAKO vp1 antiserum. 
Previously, the specificity of the DAKO vp-1 antiserum has been assessed by comparing 
immunohistochemical and enteroviral RNA detection techniques. For example, in a study of heart 
biopsies of 70 patients with dilated cardiomyopathy, enteroviral RT-PCR testing was positive in 25 
samples. Seventeen of these had focal staining of cardiac myocytes by DAKO vp1 antiserum while all 
of the RT-PCR negative samples were vp-1 negative on immunohistochemistry. All 45 normal control 
hearts were negative with both techniques [21]. Additionally, RT-PCR for enterovirus was positive in 
salivary gland biopsies in 7 of 8 patients with primary Sjogren’s syndrome but not in 16 normal 
salivary glands. Ductal, acinar and infiltrating inflammatory cells stained positively with DAKO anti-
vp-1 in the Sjogren’s cases but not in the controls [22].  
 
 
We verified that the DAKO vp1 antibody labelled human cardiac myocytes in neonates infected with 
a number of different Coxsackie B viruses in vivo, whereas non-infected neonatal heart was 
immunonegative. However, in common with others [19,23] we also noted that the DAKO antiserum 
can, under certain conditions, label tissues in which vp1 production is not expected. In particular, our 
preliminary work revealed that, when applied to formalin fixed, paraffin-embedded, sections of 
Coxsackie-infected neonatal mouse organs, this antibody stained some tissues which were reported to 
be negative for viral RNA by in situ hybridisation [24]. These included smooth muscle, bone, dental 
and hair follicle epithelium, pancreatic duct and centroacinar cells. Moreover, these tissues were also 
stained by the antibody in uninfected neonatal mice. Thus, while it is clear that the DAKO antibody is 
a sensitive agent for labelling enteroviral vp1 in a range of tissues in mouse and man, it is also evident 
that it can label non-infected cells, including, in the pancreas, vascular smooth muscle and 
centroacinar cells. However, it should be emphasized that in uninfected neonatal mice and neonatal 
children the antibody did not stain pancreatic endocrine cells. Thus, in the context of islets of 
Langerhans, the DAKO antibody stained endocrine cells only in control tissues known to be infected 
by virus. 
 
Polyclonal antisera raised against enteroviruses have been shown to cross react with hsp-60 [25] and 
the tyrosine phosphatase, IA-2 [26]. However, it seems unlikely that the DAKO vp-1 antiserum 
recognised either of these proteins in the beta cells in this study. IA-2 is present in alpha cells as well 
as beta cells while the vp-1 staining was seen in a minority of beta cells, but not alpha cells. The 
expression of hsp-60 has been studied in these diabetic samples before [27] and there was no 
equivalent staining of occasional beta cells as described here for vp-1. 
 
Because of the potential for non-specific immunoreactions with the DAKO antiserum and possible 
doubts about the origin of the virus isolated previously [13, 28] we used two additional antisera raised 
against enteroviral proteins to analyse the presence of enterovirus in sections of pancreas. With each 
of these antisera, specific enteroviral immunopositivity was first demonstrated in infected neonatal 
human hearts. Both antisera stained endocrine cells in insulin containing islets, which correlated with 
immunopositivty detected with DAKO anti-vp1 in some, but not all, type 1 diabetic patients tested. 
 
In an earlier study [13] two additional techniques were used to verify that vp1 immunostaining in 
diabetic islets represented virus infection. Firstly, virus particles were observed by electron 
microscopy, confined to beta-cells, in the same cases as had demonstrable vp-1. Secondly, a strain of 
CVB4 was isolated from one of the pancreas samples and shown to be capable of infecting normal 
human islets in vitro, leading to impaired glucose-stimulated insulin secretion [13]. While this 
evidence appears persuasive, others [28] have cast doubt on the origin of the virus strain, by 
suggesting that the reported RNA sequence analysis implies possible contamination with a laboratory 
strain.  
 
Since most of the previous studies [13,21,22] were conducted using fresh biopsy tissues, or tissues 
removed at the time of organ donation, the authors were able to employ EM, RT-PCR or in situ 
hybridization techniques to confirm the validity of the vp1 staining. These options were not open to us 
since the pancreatic material from patients with diabetes in the present study was collected almost 
entirely retrospectively from autopsies performed hours after the death of patients. In previous work 
[29] attempts were made to detect enteroviral RNA by in situ hybridization in this collection and no 
evidence of infection was found. The poor quality of RNA in formalin fixed, paraffin embedded 
autopsy pancreas, probably the result of early RNA degradation in a tissue rich in RNAse, was 
exemplified in that study by the fact that mRNA for insulin could be detected by in situ hybridization 
in only 29 of the 75 pancreases studied, even though all had insulin containing beta cells as shown by 
immunohistochemistry. In support of this, others also failed to detect viral RNA by in situ 
hybridisation in an autopsy pancreas where evidence of viral protein production was detected by 
immunohistochemistry [19]. Thus no attempt was made in the present study to repeat the search for 
enteroviral RNA by in situ hybridisation or RT-PCR. Rather, we looked at the production of another 
protein that is up-regulated in response to enteroviral infection, protein kinase R [30] and found a 
strong concordance between PKR immunopositivity and that for vp1 in the islets both type 1 and type 
2 diabetic patients. This is arguably the best evidence in the present study that detection of vp1 by the 
DAKO antibody in beta cells is indicative of a persistent enteroviral infection. 
 
While staining of vp1 correlated with PKR immunostaining in the islets of patients with type 1 
diabetes it was not seen in many of the insulin containing islets where there was hyperexpression of 
class I MHC on endocrine cells. This latter phenomenon is intimately associated with interferon-alpha 
production by beta cells [17] and is unique to type 1 diabetes [31]. Thus, vp1 staining of beta cells 
does not appear to be directly associated with secretion of interferon-alpha and it is unclear why 
interferon-alpha is produced by beta cells in those islets which hyperexpress class I MHC [26] but 
have no demonstrable viral capsid protein.  
 
In experimental acute enteroviral myocarditis in mice, viral capsid protein was most easily detectable 
by immunohistochemistry under conditions when there was an excess of positive over negative strand 
viral RNA within infected cells. By contrast, when the infection continued into a chronic phase, the 
number of positive and negative enteroviral RNA strands per cell became equivalent and capsid 
protein was less readily demonstrable [32]. On this basis, it is conceivable that a molecular form of 
virus, that is not readily detectable by immunohistochemistry for vp1, may exist as a chronic infection 
in many of the beta cells in type 1 diabetes and that, occasionally, production of the whole virus 
increases, leading to capsid protein synthesis in a small number of beta-cells. If this hypothesis is 
correct, then our results imply that the molecular form of virus detectable by vp1 immunostaining is 
also the form that most potently induces PKR production, whereas interferon-alpha may be induced 
by both molecular forms. 
 
Extending the current analysis revealed that, surprisingly, 40% of adult type 2 diabetes cases 
displayed focal staining for vp1 in their islets. The staining pattern was indistinguishable from that 
seen in the islets of patients with type 1 diabetes (though it occurred much less frequently in type 2 
diabetes) which might suggest that immunopositivity for vp1 occurs as a consequence of diabetes. 
Alternatively, enteroviral infection could play an important role in the pathology of beta-cell loss and 
malfunction in both type 1 and type 2 diabetes.  
 
The latter proposition is consistent with evidence that type 2 diabetes may be associated with islet cell 
inflammation [33] although it must also be noted that there is no induction of autoimmunity in type 2 
diabetes. Nevertheless, our present finding of production of PKR in consort with vp1 in the islets of 
patients with type 2 diabetes is consistent with an active response by infected endocrine cells to the 
presence of virus in this disease. Since non-cytopathic infection of beta-cells by enterovirus leads to 
decreased glucose-induced insulin secretion in vitro [13] it is conceivable that, in a person with 
obesity and increased insulin resistance, in whom the demand for insulin is raised, such an infection 
may contribute to beta-cell dysfunction and the development of type 2 diabetes, even if not associated 
with autoimmunity. Our findings could also suggest a similar role for enterovirus infection in 
precipitating clinical diabetes in some patients with cystic fibrosis. 
 
Vp1 staining in islets was found in ~10% of non diabetic controls of all ages. This is consistent with 
studies showing that 4-5% of normal children had enteroviral RNA in their serum [4, 7, 8] and 11.8% 
had enteroviral RNA present in faecal samples [34,35]. Since a range of enteroviruses can infect 
human islets in vitro [12,36,37] it is possible that the pancreas is frequently colonised during an 
enteroviral infection. 
 
Overall, our results are consistent with the hypothesis that enteroviral infection of beta cells at a 
young age, in patients with a genetic predisposition to type 1 diabetes, might precipitate 
autoimmunity. The islet reaction to that infection would include production of PKR, secretion of 
interferon-alpha and abnormal production of MHC molecules, leading to the type 1 form of the 
disease. Infection by a similar virus, in a person with a different genetic background, might be 
associated with PKR production, but if it did not precipitate interferon-alpha production by beta cells, 
or abnormalities of islet MHC expression in islets, this infection would not be associated with 
autoimmunity, and in the great majority of patients would lead to no clinical disease. However, in 
patients with an already compromised metabolic situation, as a result of insulin resistance, it may 
contribute to the development of type 2 diabetes. Further studies, including viral RNA detection 
techniques on fresh, organ-donation, pancreas samples from patients with recent onset disease, are 
indicated to confirm the presence and identity of enterovirus strains causing diabetes. 
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Table 1  Analysis of islet staining with 3 anti-enteroviral antisera on 11 cases of type 1 diabetes 
 
 
   Number of insulin-containing islets stained by 
Number of 
ICI 
Any 
antiserum 
Any two 
antisera 
Dako 5D8/1 Kdf 9D5 
50 12 (24%) 5 7 0 10 
31 5 (16%) 0 3 2 ND 
18 3 (17%) 0 3 0 ND 
31 9 (29%) 5 7 7 ND 
28 4 (14%) 0 4 0 0 
21 21 (100%) 19* 18 20 19 
  2 2 (100%) 0 2 0 ND 
26 18 (69%) 0 18 0 ND 
36 12 (33%) 0 12 0 ND 
23 3 (13%) 0 3 0 ND 
16 11 (18%) 0 11 0 0 
 
ND – not determined   *18islets stained by 3 antisera 
  Supplementary Table (to be available only in electronic format): Antibody details and dilutions  
Antigen Dilution Species Manufacturer 
Human Glucagon pAb 1/350 Rabbit Dako Cytomation, UK 
Swine Insulin pAb 1/400 Guinea-pig Dako Cytomation, UK 
Human CD45 mAb 1/750 Mouse Dako Cytomation, UK 
Human MHCI pAb 1/200 Rabbit Jacques Neefjes 
Enterovirus vp1 (5D8/1) mAb 1/500-1000 Mouse Dako Cytomation, UK 
Polyclonal vp1 1/400 Rabbit R.Kandolf 
Human PKR mAb 
Enterovirus mAb 9d5 
1/350 
1/10 
Rabbit 
Mouse 
Abcam, UK 
Chemicon 
 Figure legends 
Figure 1. Immunohistochemical analysis of enteroviral vp1 staining in human pancreatic islets.  
Pancreas sections from a Coxsackie-infected neonatal child (a) and two different recent-onset type 1 
diabetic patients (b, c) were stained for vp1. A serial section of the islet in (c) has also been 
immunostained for insulin (f) and shows that most beta cells do not produce vp1. Vp1 
immunoreactivity was not observed in islets from the majority of paediatric cases (d). Only 4 
positively stained islets cells were observed in 3 of 39 paediatric cases, one such cell is shown by the 
arrow in (e). The percentage of cases from each subject group that were found to have at least 1 
intensely stained cell within an islet is shown in (g). The number of positive cases/ total number of 
cases is quoted above each respective bar. 
 
Figure 2. Enteroviral vp1 production is restricted to insulin-containing beta cells. (a) Analysis of serial 
sections stained for vp1, insulin and glucagon was used to determine the percentage of insulin-
containing islets (ICIs; black bars) and of insulin-deficient islets (IDIs; white bars) that stained 
positively for vp1. The results presented are from 10 recent-onset type 1 diabetic cases which had vp1 
positive endocrine cells; a total of 342 ICIs and 611 IDIs were analysed. Of these 269 and 16 were 
vp1 positive respectively. (b) Confocal microscopic analysis of representative islets reveals that vp1 
(red; panels b,c,e,f) co-localised with insulin (green; panels a,c) but not with glucagon (panels d,f). 
Those stained in yellow are double-positive cells (panels c,f). 
 
Figure 3. Comparison of the staining patterns obtained in Coxsackie-infected neonatal heart with two 
antisera raised against vp1. Sections of Coxsackie-infected neonatal human heart were stained with 
either the DAKO vp1 5D8/1 antibody (a) or the Kdf vp1 antibody (b).  
 
Figure 4: Comparison of the staining patterns obtained in human type 1 diabetic pancreas with three 
different antisera raised against enteroviral antigens. Representative islets from two different type 1 
diabetic pancreases, a-d, e-f, were stained with DAKO vp1 antibody (a,e), kdf vp1 (b,f), the anti-
enteroviral antibody 9d5 (c) and insulin (d).  
Figure 5.  Examination of vp1 immunopositivity, production of PKR and hyper-expression of MHC 
class I in the islets of recent-onset type 1 diabetic patients and a patient with type 2 diabetes.  (a) Two 
representative islets from recent-onset type 1 diabetic patients and one from a patient with type 2 
diabetes were stained for insulin, vp1, protein kinase R (PKR) and MHC Class I (MHCI).  The upper 
panel shows an insulin-containing islet (ICI) and the middle panel an insulin-deficient islet (IDI) from 
a patient with type 1 diabetes (T1D), while the lower panel shows an islet from a type 2 diabetic 
patient (T2D). In the lower panel note that the same cells within the islet stain with vp1 and PKR on 
these adjacent sections. (b) Detailed analysis of 177 insulin-containing islets (ICIs) from 6 
representative vp1 positive type 1 patients demonstrates that vp1 is associated with PKR production in 
154 (87%) of these ICIs. 
 
Figure 6. Immunostaining of vp1 in pancreas sections from patients with type 2 diabetes.  
Representative islets from a normal adult (Ai) or a patient with type 2 diabetes (Aii) were stained for 
vp1. In these cases, centroacinar (Aiii) and smooth muscle A(iv) cell staining was also observed. (B): 
analysis of the percentage of cases from each subject group that have at least 1 intensely stained cell 
within an islet. (C): detailed analysis of the frequency of vp1 immunopositivity within insulin-
containing islets in patients with type 1 diabetes (n=10), type 2 diabetes (n=6) and normal adults 
(n=7). (D): detailed analysis of PKR and vp1 production in up to 50 randomly selected ICIs from 9 
Type 2 diabetic patients (339 islets; black bars) and 9 normal adult (403 islets; white bars).  
 
  
 
